INDO US BIOTECH
INDOUS · NSE
73.54
-4.82 (-6.15%)
as of 30 Oct 2026 close
Open
79.79
High
83.48
Low
72.00
Prev close
78.36
52w high
159.00
27 Nov 2025
52w low
57.50
26 Oct 2026
VWAP
78.73
Delivery %
32.2%
of volume
Volume 47,856 · turnover ₹37.68 L · NSE bhavcopy (official close) · history since 27 Sept 2024
- Market cap
- ₹147 cr
- ISIN
- INE250Z01010
- Series
- EQ
- Listed on NSE
- 27 Sept 2024
- Face value
- ₹10
- F&O
- No
Source: NSE equity master · as of 31 Oct 2026 · market cap = shares (30 Sept 2026 filing) × close
Market cap
₹147 cr
P/B
1.60
BV ₹46
ROE (TTM)
—
Debt / equity
0.48
P/E (TTM)
—
P/S (TTM)
—
Revenue TTM
—
Net profit TTM
—
Net margin TTM
—
EV / EBITDA
—
Interest cover
—
Revenue growth
—
latest quarter YoY
Profit growth
—
latest quarter YoY
Dividend yield
—
last 12 months
Standalone · last four quarters to 2026-09-30 · balance sheet 2026-09-30 · tap a tile for the formula
Daily · NSE EOD
Shareholding · as of 30 Sept 2026
Promoters
68.29%
+0.00 pp QoQ
Public
31.71%
FPIs 0.01%
DIIs 0.25%
Mutual funds —
Insurance —
Retail 24.48%
Government —
26-06
26-09
Promoter share by quarter · source: NSE shareholding filings (XBRL). DIIs include mutual funds and insurers.
Quarterly results · Standalone · latest 30 Sept 2026
filed 30 Oct 2026, 04:20 pm IST| ₹ crore | Jun 26* | Sept 26* |
|---|---|---|
| Revenue | 33 | 15 |
| Other income | 0 | 0 |
| Total expenses | 30 | 19 |
| Operating margin | 12.0% | -17.3% |
| Finance costs | 1 | 1 |
| Depreciation | 0 | 0 |
| Profit before tax | 3 | -4 |
| Tax | 0 | 0 |
| Net profit | 3 | -4 |
| Net margin | 9.2% | -24.4% |
| EPS (₹) | 1.51 | -1.83 |
Source and definitions
NSE financial-results filings (XBRL / integrated filing). Figures exactly as filed with NSE in the company's results, converted to ₹ crore from the filing's own rounding. Operating margin = (PBT + finance costs + depreciation − other income) ÷ revenue. Net margin = net profit ÷ revenue. * = unaudited quarter. Consolidated figures are shown when the company files them; otherwise standalone.
Coming next in fundamentals
Arrives in Phase 2. Nothing here is estimated or filled in — we only show data we have.
- P/E, P/B, EV/EBITDA, ROE, ROCE (needs balance sheet + market cap)
- FII / DII / mutual fund split (from shareholding XBRL)
- Peer comparison